Beijing Med-Pharm to market Enablex in China

Under the terms of the agreement, Beijing Med-Pharm is responsible for attaining SFDA approval of Enablex, a process that is expected to last through 2010. Once approved, Beijing Med-Pharm will have the exclusive rights to sell, market and distribute Enablex in China for 10 years.

Enablex is a prescription medicine used in adults to treat symptoms of urinary incontinence, urgency and urinary frequency related to an overactive bladder (OAB).

David Gao, CEO of Beijing Med-Pharm, said: “The potential sales opportunity for Enablex is extremely compelling in China. There are currently few medications available to combat OAB and, concurrently, millions of Chinese have not yet accessed treatment. While we are seeking SFDA approval, we plan to educate doctors and patients on OAB.”